SAR405 NEW
| Price | $54 |
| Package | 1mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-04 |
Product Details
| Product Name: SAR405 | CAS No.: 1523406-39-4 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2025/11/04 |
Product Introduction
Bioactivity
| Name | SAR405 |
| Description | SAR-405 is a potent and selective PIK3C3/Vps34 inhibitor (IC50:1.2 nM; Kd:1.5 nM) that prevents autophagy and synergizes with MTOR inhibition in tumor cells. SAR405 treatment also inhibits autophagy induced either by starvation or by MTOR (mechanistic target of rapamycin) inhibition. Combining SAR405 with everolimus results in a significant synergy on the reduction of cell proliferation using renal tumor cells. |
| In vitro | SAR405, a low molecular mass kinase inhibitor of PIK3C3, highly potent and selective with regard to other lipid and protein kinases. Inhibiting the catalytic activity of PIK3C3 disrupts vesicle trafficking from late endosomes to lysosomes. SAR405 treatment also inhibits autophagy induced either by starvation or by MTOR (mechanistic target of rapamycin) inhibition. SAR405 prevents autophagosome formation (IC50: 42 nM). Treatment of starved cells with SAR405 fully inhibits the conversion to LC3-II in a dose-dependent manner. The GFP-LC3 model is used for the HTS and confirmed its activity on starved cells (IC50=419 nM) [1][2]. |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 27 mg/mL (60.83 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.51 mM), Sonication is recommended. |
| Keywords | Vps34 | SAR-405 | SAR405 | SAR 405 | PI3K | Phosphoinositide 3-kinase | Inhibitor | inhibit | Autophagy |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | Alginic acid | Gefitinib |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Anti-Lung Cancer Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Prostate Cancer Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Oxidation-Reduction Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY